ClinicalTrials.gg
RecruitingNCT07944560DEESPITEUpdated Nov 18, 2026

Development of dEep EndometrioSis Following Acute haemoPerITonEum

An observational study in Hemoperitoneum, Pelvic Pain and Endometriosis, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
32
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Pelvic Pain with a site in Italy — 3 open to participants now, 4 under way, none of them phase 3. Pelvic Pain · Italy.

Started
2026
with 1 other
Observational
6 of 12
3 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Among the 12 studies in Pelvic Pain with a site in Italy, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 12th registered.

Pelvic Pain

376 studies on the registry are indexed under Pelvic Pain; 90 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

3 of the 12 studies in Pelvic Pain with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 60 Pelvic Pain studies recruiting now, 22 (37%) set no upper age limit and 36 (60%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pelvic Pain with a site in Italy, or all of them as a file.
02

Study summary

This study investigates whether acute pelvic pain with haemoperitoneum is associated with an increased risk of developing deep pelvic endometriosis, compared with acute pelvic pain without haemoperitoneum. Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to a single follow-up visit, including a transvaginal ultrasound and validated questionnaires.

Read the detailed description

This is a single-centre, non-pharmacological, interventional, no-profit study conducted at the Obstetric-Gynecological Emergency Department and the Infertility Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.

Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to participate. Cases are women with documented haemoperitoneum and no previous diagnosis of endometriosis. Controls are women with acute pelvic pain without haemoperitoneum and no previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year). Women with previous hysterectomy or oophorectomy, or established menopause, are excluded.

Participants who provide informed consent will attend a single follow-up visit, lasting approximately one hour. The visit includes a second-level transvaginal ultrasound to identify lesions suggestive of deep endometriosis according to the IDEA criteria, and validated questionnaires assessing quality of life (SF-12), endometriosis-specific quality of life (EHP-30), sexual function (FSFI) and pain (NRS).

The primary outcome is the incidence of sonographically diagnosed deep pelvic endometriosis between 6 months and up to 5 years after the acute event, comparing cases and controls. Secondary outcomes include the impact of the acute event on chronic pelvic pain and quality of life, and the association between treatment of the acute event (surgical vs conservative) or use of hormonal therapy during follow-up and the development of endometriosis.

03

Conditions studied

  • Hemoperitoneum
  • Pelvic Pain
  • Endometriosis

Keywords

  • endometriosis
  • haemoperitoneum
  • deep endometriosis
  • pelvic pain
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-50 years
  • Female sex
  • Attendance at the Obstetric-Gynecological Emergency Department (Clinica Mangiagalli) for acute pelvic pain
  • For cases: documented haemoperitoneum without a previous diagnosis of endometriosis
  • For controls: no documented haemoperitoneum without a previous diagnosis of endometriosis

Exclusion criteria

Exclusion Criteria:

  • Previous hysterectomy and/or oophorectomy
  • Established menopause
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
32 participants (estimated)
Patient registry
No

Groups and cohorts

  • Haemoperitoneum

    Women aged 18-50 with acute pelvic pain and documented haemoperitoneum, without a previous diagnosis of endometriosis

  • No haemoperitoneum

    Women aged 18-50 with acute pelvic pain and no documented haemoperitoneum, without a previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year)

06

What researchers measure

Primary outcomes

  1. Incidence of sonographically diagnosed deep pelvic endometriosis

    Incidence of deep pelvic endometriosis diagnosed by second-level transvaginal ultrasound according to IDEA criteria, comparing cases (haemoperitoneum) and controls (no haemoperitoneum)

    Time frame: From 6 months up to 5 years after the acute event

Secondary outcomes

  1. Pelvic pain intensity assessed using the Numeric Rating Scale (NRS)

    Comparison of pelvic pain intensity between participants with and without haemoperitoneum at the index acute event, assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.

    Time frame: From 6 months up to 5 years after the acute event

  2. Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30)

    Comparison of the Endometriosis Health Profile-30 (EHP-30) overall summary score between participants with and without haemoperitoneum at the index acute event. The core questionnaire contains 30 items, each scored from 0 to 4. A single overall score is calculated by summing the scores of all 30 items, dividing the sum by the maximum possible score of 120, and multiplying by 100. The overall score ranges from 0 to 100, with higher scores indicating worse health-related quality of life.

    Time frame: From 6 months up to 5 years after the acute event

  3. Quality of life assessed using the Short Form Health Survey (SF-12)

    Comparison of the 12-Item Short Form Health Survey (SF-12) scores between participants with and without haemoperitoneum at the index acute event. Scores will be calculated using the questionnaire's standard scoring algorithm. Norm-based scores have a reference population mean of 50 and a standard deviation of 10, with higher scores indicating better physical health-related quality of life.

    Time frame: From 6 months up to 5 years after the acute event

  4. Sexual function assessed using the Female Sexual Function Index (FSFI)

    Comparison of Female Sexual Function Index (FSFI) total scores between participants with and without haemoperitoneum at the index acute event. The FSFI is a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Weighted domain scores are summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function.

    Time frame: From 6 months up to 5 years after the acute event

  5. Odds ratio for endometriosis diagnosis according to initial treatment

    Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants initially managed surgically with those managed conservatively. Initial treatment will be classified from medical records. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no).

    Time frame: From 6 months up to 5 years after the acute event

  6. Odds ratio for endometriosis diagnosis according to hormonal therapy use

    Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants who received hormonal therapy during follow-up with those who did not. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no).

    Time frame: From 6 months up to 5 years after the index acute event.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 33 observational studies under Pelvic Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944560
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Apr 30, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Edgardo Somigliana, PhD
Contact
procreazioneassistita@policlinico.mi.it
+39 0255034311
Marco Reschini, MSc
Contact
procreazioneassistita@policlinico.mi.it
+39 0255034311

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion